Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 26;11:3256. doi: 10.1038/s41467-020-16936-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 8 — a Effect of combined treatment of cisplatin with ATR, ATM or CHK1 inhibitors on HCC1937 cells; n = 4 biologically independent experiments. b Quantification analysis of combined drug treatment in HCC1937 cells. Cisplatin (2.5 µM), ATR, ATM or CHK1 inhibitor (0.5 µM); n = 3 biologically independent experiments. c Killing effect on TNBC cells treated with cisplatin combined with different inhibitors. The colour in the heatmap represents the relative values of the areas under the curves. d In vivo effect of cisplatin combined with ATR inhibitor (AZD6738) on tumours in the PDX model (TM00091), which carries the BRCA1 mutation and highly expresses NOTCH1. Six mice were used for each treatment group. e IHC staining of Ki67 and cleaved caspase-3 in PDX tumours after drug treatment. Five tumours from different mice were examined for each treatment group. f Quantification analysis of dead cells (arrowhead), including cleaved caspase-3-positive cells (arrow) in each treatment group. Six to ten areas from different tumours were counted. g Illustration of the ICN1 function for TNBC formation in BRCA1-defective conditions. The t-test was used to determine the significance of differences between the different sets of data. Data are presented as mean values ± s.d. * indicates p < 0.05.